Study guide
6.2 Organophosphate, Paracetamol & Snakebite Toxicology
Combined Medical Services Examination UPSC CMS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Logistics & Pattern
1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths
2 Chapter 2: General Medicine - Cardiology & Respiratory
2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism
3 Chapter 3: General Medicine - Gastroenterology & Hepatology
3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes
4 Chapter 4: General Medicine - Nephrology & Endocrinology
4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction
5 Chapter 5: General Medicine - Neurology, Haematology & Infection
5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue
6 Chapter 6: General Medicine - Emergency Medicine & Toxicology
6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology
7 Chapter 7: Paediatrics - Neonatology & Child Growth
7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones
8 Chapter 8: Paediatrics - Child Health & Nutrition
8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning
9 Chapter 9: Surgery - General Surgery, Wounds & Shock
9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery
10 Chapter 10: Surgery - Surgical Specialties I
10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi
11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia
11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease
12 Chapter 12: Obstetrics - Antenatal Care & Complications
12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management
13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH
13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care
14 Chapter 14: Gynaecology & Family Planning
14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods
15 Chapter 15: PSM - Epidemiology & Biostatistics
15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing
16 Chapter 16: PSM - Disease Epidemiology & Programmes
16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling
17 Chapter 17: PSM - Health Planning & Environmental Health
17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education
6.2 Organophosphate, Paracetamol & Snakebite Toxicology
Key Takeaways Explain This Topic AI
Organophosphate poisoning results in a cholinergic crisis due to acetylcholinesterase inhibition; Atropine is the essential antidote for muscarinic hypersecretory symptoms (titrated until lung crepitations clear and HR > 80 bpm), while Pralidoxime (PAM) reactivates acetylcholinesterase at nicotinic sites.
Paracetamol (Acetaminophen) toxicity causes centrilobular hepatic necrosis via accumulation of N-acetyl-p-benzoquinone imine (NAPQI) when hepatic glutathione stores are depleted by > 70%; N-Acetylcysteine (NAC) is the specific antidote, most effective within 8 hours of ingestion.
The Rumack-Matthew Nomogram is used to predict hepatotoxicity risk and guide N-Acetylcysteine therapy based on a serum paracetamol level drawn between 4 and 24 hours after an acute single ingestion.
Venomous snakebites in India present as either neurotoxic (Common Krait, Spectacled Cobra) with descending ptosis and respiratory paralysis, or hemotoxic/vasculotoxic (Russell's Viper, Saw-scaled Viper) with local necrosis and systemic coagulopathy.
The 20-Minute Whole Blood Clotting Test (20WBCT) is a simple bedside test for hemotoxic snakebite coagulopathy; non-clotting blood is an absolute indication for initial 10 vials of Polyvalent Anti-Snake Venom (ASV) IV.
Last updated: July 2026
Organophosphate, Paracetamol & Snakebite Toxicology
Toxico-emergencies represent one of the most high-yielding areas of emergency medicine in UPSC CMS examinations. Command over antidote mechanisms, toxicodynamics, clinical endpoints of therapy, and bedside testing is crucial for solving clinical vignettes.
1. Organophosphate & Carbamate Insecticide Poisoning
Organophosphate (OP) compounds (e.g., Malathion, Parathion, Chlorpyrifos, Dichlorvos) are widely used agricultural insecticides in India and represent a common cause of accidental and intentional self-poisoning.
Pathophysiology
Organophosphates inhibit the enzyme Acetylcholinesterase (AChE) by phosphorylating its active esteratic site. This causes toxic accumulation of acetylcholine (ACh) at parasympathetic postganglionic junctions (muscarinic), neuromuscular junctions (nicotinic), and central nervous system synapses. Over time (hours to days), the enzyme-poison complex undergoes "aging" (dealkylation), making the AChE inhibition permanent and resistant to reactivating oximes.
Clinical Features: The Cholinergic Toxidrome
Muscarinic Effects (DUMBELS) :
- D : Diarrhea / Diaphoresis
- U : Urination
- M : Miosis (pinpoint pupils)
- B : Bronchorrhea & Bronchospasm ( Primary cause of death due to asphyxiation and pulmonary edema )
- E : Emesis
- L : Lacrimation
- S : Salivation
Nicotinic Effects (MTWThF) : Muscle fasciculations (tongue, eyelids, chest wall), Tachycardia, Weakness, Hypertension, and flaccid Paralysis.
Central Nervous System : Confusion, agitation, seizures, central respiratory depression, coma.
Complications Delayed in Time
Intermediate Syndrome (IMS) : Occurs 24 to 96 hours post-exposure following initial recovery from cholinergic crisis. Caused by persistent dysfunction at neuromuscular junctions. Characterized by weakness of neck flexors, proximal limb muscles, cranial nerve-innervated muscles, and respiratory muscles leading to sudden respiratory failure. Requires mechanical ventilation .
Organophosphate-Induced Delayed Polyneuropathy (OPIDN) : Occurs 2 to 3 weeks after exposure due to inhibition of Neuropathy Target Esterase (NTE) . Manifests as a distal, symmetrical sensory-motor peripheral neuropathy ("foot drop" and stocking-glove sensory loss).
Emergency Management Protocol
Decontamination & Resuscitation : Remove all contaminated clothing; wash skin thoroughly with soap and water. Secure airway and administer oxygen. Perform gastric lavage ONLY after airway is protected by endotracheal intubation.
Antidote #1 — Atropine (Competitive Muscarinic Antagonist) :
Dose : Initial IV bolus of 1.8 to 3.0 mg (or 2–5 mg IV). Double the dose every 5 to 10 minutes if no response.
Endpoints of Atropinization :
Clear chest on auscultation (disappearance of bronchorrhea and pulmonary crepitations) — MOST IMPORTANT CLINICAL ENDPOINT!
- Heart Rate > 80–100 beats/min
- Systolic BP > 90 mmHg
- Dry skin and axillae
Pupils mid-dilated or dilated (Note: pupil size alone is NOT a reliable endpoint!).
Maintenance : Once atropinized, start continuous IV atropine infusion at 10–20% of the total dose required for initial atropinization per hour.
Antidote #2 — Oximes (Pralidoxime / 2-PAM) :
Mechanism : Nucleophilic reactivators of phosphorylated acetylcholinesterase before aging occurs. Effective against nicotinic signs (muscle fasciculations and weakness).
Dose : Loading dose of 1 to 2 g IV in 100 mL Normal Saline over 30 minutes, followed by continuous IV infusion of 500 mg/hour.
Contraindications : Avoid Morphine, Aminophylline, Succinylcholine, and Phenothiazines.
2. Paracetamol (Acetaminophen) Hepatotoxicity
Paracetamol is a benign analgesic at therapeutic doses (max 4 g/day in adults) but causes severe, acute centrilobular hepatic necrosis in overdose (> 150 mg/kg or > 7.5–10 g single ingestion).
Pathophysiology & Toxicokinetics
At therapeutic doses, 90% of paracetamol undergoes phase II hepatic conjugation via glucuronidation and sulfation into non-toxic, water-soluble metabolites excreted in urine.
~5–10% is metabolized by the cytochrome P450 enzyme CYP2E1 into N-acetyl-p-benzoquinone imine (NAPQI) , a highly toxic, electrophilic intermediate.
Under normal conditions, NAPQI is immediately detoxified by conjugation with endogenous hepatic Glutathione to form non-toxic mercapturic acid.
In paracetamol overdose, the glucuronidation and sulfation pathways become saturated. Excess paracetamol is shunted to CYP2E1, generating massive amounts of NAPQI that deplete hepatic glutathione stores by > 70–80% .
Unbound NAPQI covalently binds to cysteine sulfhydryl groups on hepatocellular proteins, causing mitochondrial dysfunction, oxidative stress, and centrilobular (Zone 3) hepatic necrosis .
Stages of Paracetamol Poisoning
Stage I (0–24 hours) : Anorexia, nausea, vomiting, diaphoresis, malaise. LFTs are normal.
Stage II (24–72 hours) : Subclinical onset of hepatotoxicity. Right upper quadrant abdominal pain and hepatomegaly. AST and ALT rise rapidly (often > 1,000–10,000 U/L), along with elevation of PT/INR and bilirubin.
Stage III (72–96 hours) : Peak hepatotoxicity. Jaundice, marked coagulopathy, hepatic encephalopathy, hypoglycemia, lactic acidosis, and acute kidney injury (acute tubular necrosis).
Stage IV (4–14 days) : Recovery phase for survivors, with complete histological resolution over weeks.
Management & Antidote Protocol
Activated Charcoal : 1 g/kg orally if patient presents within 1 to 2 hours of ingestion.
Rumack-Matthew Nomogram : Used for acute single ingestions. Obtain serum paracetamol concentration at least 4 hours post-ingestion . Plot the level on the nomogram:
Treatment line starts at 150 mcg/mL (1000 umol/L) at 4 hours (or 37.5 mcg/mL at 12 hours).
If the level lies on or above the treatment line, initiate antidote therapy immediately.
Specific Antidote — N-Acetylcysteine (NAC) :
Mechanism : Precursor for glutathione synthesis; directly combines with NAPQI; acts as an antioxidant and anti-inflammatory agent improving microvascular perfusion.
Efficacy : Almost 100% protective against severe hepatotoxicity when administered within 8 hours of acute ingestion.
Oral Protocol (Prescott) : 140 mg/kg loading dose, followed by 70 mg/kg every 4 hours for 17 maintenance doses (total 72-hour regimen).
IV Protocol (3-Stage 20-Hour Infusion) :
150 mg/kg in 200 mL 5% Dextrose over 1 hour.
50 mg/kg in 500 mL 5% Dextrose over 4 hours.
100 mg/kg in 1000 mL 5% Dextrose over 16 hours (Total dose: 300 mg/kg).
3. Snakebite Toxicology in India
Snakebite envenomation is a significant neglected tropical disease causing high mortality in rural India. The vast majority of fatal bites are caused by the "Big Four" venomous snake species :
Snake Species Family Venom Type Key Clinical Features
Spectacled Cobra ( Naja naja ) Elapidae Neurotoxic + Local cytotoxic Post-synaptic neuromuscular blockade; local pain, swelling, tissue necrosis
Common Krait ( Bungarus caeruleus ) Elapidae Highly Neurotoxic Pre-synaptic neuromuscular destruction; painless nocturnal bites, abdominal colic, early morning paralysis
Russell's Viper ( Daboia russelii ) Viperidae Vasculotoxic / Hemotoxic + Nephrotoxic Severe local edema, ecchymosis, systemic hemorrhage, DIC, acute renal failure
Saw-scaled Viper ( Echis carinatus ) Viperidae Vasculotoxic / Hemotoxic Marked local swelling, procoagulant action, bleeding from gums/wounds, hypofibrinogenemia
- Clinical Presentation & Syndromes
- A. Neurotoxic Envenomation (Elapid Bites)
Cobra & Krait : Venom toxins disrupt acetylcholine transmission at the neuromuscular junction.
Earliest Clinical Sign : Bilateral Ptosis (drooping of eyelids) and external ophthalmoplegia.
Progression : Descending paralysis involving facial muscles, dysarthria, dysphagia, pooling of secretions, weakness of neck flexors, and finally flaccid paralysis of intercostal muscles and diaphragm leading to respiratory arrest .
Krait Specifics : Bites frequently occur at night while victim is sleeping on the floor. The bite is virtually painless with minimal local swelling. Patients present with severe paroxysmal abdominal pain (colic) followed by morning neuroparalysis.
Neostigmine Challenge Test : Cobra venom contains post-synaptic neurotoxins (alpha-neurotoxins) that reversibly block nicotinic ACh receptors. Patients with Cobra bites show dramatic improvement with Neostigmine (0.5–2.5 mg IV) plus Atropine (0.6 mg IV). Krait venom contains pre-synaptic neurotoxins (beta-bungarotoxin) which destroy nerve terminals, making them unresponsive to Neostigmine; mechanical ventilation is crucial.
B. Vasculotoxic / Hemotoxic Envenomation (Viper Bites)
Viperidae Venom : Contains hemorrhagins, zinc metalloproteinases, and procoagulant enzymes (prothrombin and Factor X activators) that consume fibrinogen and platelets.
Local Features : Severe rapidly progressive swelling, erythema, severe pain, blistering, necrotic bullae, and compartment syndrome.
Systemic Features : Spontaneous systemic bleeding (gingival bleeding, epistaxis, hematemesis, melena, hematuria, hemoptysis, intracranial hemorrhage), hypotension, acute kidney injury (due to acute tubular necrosis or cortical necrosis in Russell's viper), and Disseminated Intravascular Coagulation (DIC).
Bedside Diagnostic Test: 20-Minute Whole Blood Clotting Test (20WBCT)
The 20WBCT is the single most reliable bedside screening test for venom-induced consumption coagulopathy in viperine bites:
Take 2 mL of fresh venous blood drawn from an un-infused vein.
Place into a clean, dry, un-siliconized glass test tube .
Leave undisturbed for 20 minutes at ambient room temperature.
Incline the tube gently.
Normal Result (Clotted) : Blood has formed a firm clot.
Positive Result (Incomplete / Non-Clotting) : Blood remains completely liquid. Indicates severe hypofibrinogenemia (< 50 mg/dL) due to hemotoxic envenomation — Mandatory indication for Anti-Snake Venom (ASV) .
Polyvalent Anti-Snake Venom (ASV) Protocol
In India, Polyvalent ASV is produced by hyper-immunizing horses against the venom of all Big Four species (Cobra, Krait, Russell's Viper, Saw-scaled Viper).
Indications for ASV
Systemic Envenomation :
Neurotoxic signs (ptosis, diplopia, respiratory distress).
Hemotoxic signs (positive 20WBCT, spontaneous systemic bleeding).
Cardiovascular collapse, shock, or arrhythmias.
Acute Kidney Injury / hemoglobinuria / myoglobinuria.
Severe Local Envenomation : Rapidly spreading swelling involving more than half of the bitten limb within 3–4 hours.
Dosing & Administration
Initial Loading Dose : 10 vials (100 mL) of reconstituted polyvalent ASV.
Method of Administration : Reconstitute each vial in 10 mL of sterile water. Dilute the 10 vials (100 mL) in 240–500 mL of 0.9% Normal Saline or 5% Dextrose. Infuse intravenously over 1 hour (start slow at 1–2 mL/min for first 10 minutes while observing for anaphylaxis).
Local Injection : NEVER inject ASV locally into the bite site or ring-block the finger/toe.
Repeat Doses :
Hemotoxic Bites : Re-assess 20WBCT after 6 hours . If blood remains non-clotting, repeat 5 to 10 vials of ASV. Repeat every 6 hours until clotting is restored.
Neurotoxic Bites : If neuroparalysis worsens or fails to improve after 1 to 2 hours , administer a second dose of 10 vials of ASV.
ASV Reaction Management : If severe anaphylactoid reaction occurs during infusion, temporarily stop ASV, administer Adrenaline 0.5 mg IM , IV Hydrocortisone, and Chlorpheniramine. Resume ASV at a slower rate once reaction resolves.